SKYE

Skye Bioscience, Inc. (SKYE) - Q1 2026 10-Q Summary

Business Context and Reporting Period

Skye Bioscience, Inc. is a clinical-stage biotechnology company developing nimacimab, a peripherally restricted negative allosteric modulating antibody targeting the CB1 receptor for the treatment of obesity and overweight. This report covers the quarterly period ended March 31, 2026. The Company has not yet generated revenue and relies on capital raises to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $1.4 million year-over-year, driven by higher R&D spending.
• R&D Expense Growth: R&D expenses rose by $738,423 (10%) due to increased clinical trial site/patient costs, contract manufacturing for the Phase 2a extension, and stock-based compensation from option repricing.
• Liquidity Reduction: Total unrestricted cash and short-term investments decreased from $25.7 million (Dec 31, 2025) to $17.1 million (March 31, 2026). This was primarily due to operating cash burn of $8.6 million, partially offset by the maturity of $10.9 million in short-term investments.
• Legal Liability Adjustment: The estimated legal contingency for the "Cunning Lawsuit" increased by $505,692 to $2.57 million due to accrued legal expenses for the upcoming retrial.
• Stock-Based Compensation: Total stock-based compensation decreased to $1.5 million from $2.2 million in the prior year, despite a one-time incremental expense of $339,063 related to a stock option repricing event.

Guidance, Outlook, and Risks

• Clinical Progress:
  • Phase 2a (CBeyond): Monotherapy (200mg) did not meet primary weight loss endpoint vs. placebo. However, combination therapy with semaglutide showed statistically significant weight loss (-13.2% vs -10.25% for semaglutide alone).
  • Extension Study: Interim data from the combination arm extension showed mean weight loss of 22.3% at 52 weeks. Full topline data expected in Q3 2026.
  • Expansion Study (Part C): Initiated in March 2026 to assess IV dosing (400mg/600mg). Topline data expected Q4 2026.
• Capital Resources & Going Concern: Management estimates sufficient capital to fund operations through Q4 2026, excluding costs for a potential Phase 2b study. The filing explicitly states there is substantial doubt about the Company's ability to continue as a going concern within one year of the report date due to recurring losses and the need for additional financing.
• Nasdaq Listing Deficiency: The Company received a notice from Nasdaq on March 17, 2026, regarding failure to maintain the $1.00 minimum bid price for 30 consecutive days. The Company has 180 days (until September 14, 2026) to regain compliance, potentially via a reverse stock split.
• Legal Risks: A new trial for the "Cunning Lawsuit" (wrongful termination/whistleblower) is scheduled for May 2026. Additionally, a securities class action and derivative lawsuits were filed in late 2025/early 2026 alleging false statements regarding nimacimab efficacy.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and the exclusion of Phase 2b costs from the current runway estimate.
• Nasdaq Compliance: Monitor the stock price and any announcements regarding a reverse stock split to avoid delisting.
• Legal Exposure: Track the outcome of the May 2026 retrial in the Cunning Lawsuit and the status of the securities class action, as these could materially impact liquidity.
• Clinical Data: Await Q3 2026 topline data for the Phase 2a extension to confirm the durability of the combination therapy results.
• Debt Obligations: Note the $250,338 insurance premium loan payable maturing in October 2026.